GMAB Genmab A/S
$37.02
▼ 2.1%Updated Oct 16, 2:25 PM ET
Report Card
GMAB at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: Favorable · 62/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Price — Past Year
▲ Up 38.4% in the year to Jul 6, 2026
Key Metrics
Market Cap
$16.18B
P/E
20.86x
Forward P/E (est.)
27.91x
ROE
14.5%
Revenue Growth
20.7%
EPS Growth
-25.3%
Profit Margin
21.1%
FCF Yield
—
Debt / Equity
0.93x
ROIC
8.0%
Interest Coverage
3.96x
Current Ratio
2.02x
Dividend Yield
—
Implied Growth (rev. DCF)
1.8%
Rating Score
62/100
Business Overview
Genmab A/S (GMAB) is a large-cap NASDAQ-listed company in the Biotechnology industry, within the Health Care sector, with a market value around $16.18B.
In its latest reported year it generated about $3.72B in revenue and $963.00M in net profit.
Our model rates GMAB Favorable (62/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical Analysis (Educational)
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what GMAB's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. GMAB trades near $37.02, above its 50-day average ($26.22) and 200-day average ($29.22). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 78 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. GMAB's is $0.83 (~2.2% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. In the month to Jul 6, 2026, GMAB found buyers near $24.08 (support) and sellers near $28.78 (resistance); its 52-week range then was $20.23–$35.43. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.4× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. The indicators were last computed on Jul 6, 2026; the price is current.
Revenue Growth
2Y CAGR
24.8%
Revenue moved from $2.39B in 2023 to $3.72B in 2025, a 24.8% compound annual growth rate. The most recent year grew a strong 20.7% year over year. Consistent top-line growth is one sign of healthy demand.
Profitability
Gross Margin
93.3%
Operating Margin
28.6%
Net Margin
25.9%
ROE
14.5%
Genmab A/S keeps about 21.1% of each sales dollar as net profit, with a 93.3% gross margin and 28.6% operating margin. Return on equity is 14.5% and return on invested capital about 8.0%. Margins this wide usually signal pricing power or a cost advantage.
Debt Analysis
Total Debt
$5.00B
Net Debt
$3.29B
Net Debt / EBITDA
3.09x
Debt / Equity
0.93x
Leverage: debt-to-equity is 0.9x, and operating profit covers interest about 4.0x, with a current ratio of 2.0x. That is a moderate, manageable debt load for most businesses. It carries roughly $5.00B of total debt against $1.72B of cash.
Cash Flow Analysis
Operating CF
$1.19B
Free Cash Flow
$1.15B
FCF Margin
30.9%
In the latest year Genmab A/S produced about $1.19B of operating cash flow and $1.15B of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Valuation Analysis
P/E
20.86x
P/S
4.6x
P/B
3.27x
EV / EBITDA
18.18x
GMAB trades at 20.9x trailing earnings (about 27.9x on estimated forward earnings), 4.6x sales, and 3.3x book value. Reverse-engineering today's price implies the market expects roughly 1.8% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
DCF Fair Value (Educational)
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
How this DCF estimate is calculatedDCF fair value / share
$14,517.43
Current price
$37.02
Starting FCF (latest 10-K)
$1.15B
Growth, years 1–5
20.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Metrics vs. Sector Range
Where GMAB sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How GMAB stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
Among the 83 rated Health Care companies we cover, GMAB ranks #25 by our overall rating. It trades at a discount versus the sector on earnings (20.9x P/E vs. 26.1x median) with a higher return on equity (14.5% vs. 14.1%) and faster revenue growth (20.7% vs. 7.6%).
P/E vs sector
20.9x
median 26.1x
ROE vs sector
14.5%
median 14.1%
Growth vs sector
20.7%
median 7.6%
Sector rank
#25
of 83 rated
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$74.63 – $120.55
vs. $37.02 today · implied CAGR 15% – 27%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $4.50B | $5.45B | $6.59B | $7.97B | $9.65B |
| Net income | $1.17B | $1.42B | $1.71B | $2.07B | $2.51B |
| EPS | $2.68 | $3.24 | $3.92 | $4.74 | $5.74 |
| Share price (low) | $34.81 | $42.12 | $50.97 | $61.67 | $74.63 |
| Share price (high) | $56.24 | $68.05 | $82.34 | $99.63 | $120.55 |
| CAGR (low–high) | -6% / 52% | 7% / 36% | 11% / 31% | 14% / 28% | 15% / 27% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions.
Bull Case
The case for GMAB:
- Revenue is growing 20.7% a year, a sign of real demand.
- High net margins (21.1%) point to pricing power or efficiency.
- Our model's overall read is Favorable (62/100).
Bear Case
The case against GMAB:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Key Risks
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Investment Thesis
On balance, the fundamentals screen favourably: Genmab A/S is a large-cap health care business still growing nicely, with solid profitability, and a heavier debt load to watch. It trades at 20.9x earnings, which our model scores Favorable (62/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 27 Wall Street analysts covering GMAB recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more positive over the last three months (+5 pts of buy ratings).
Latest SEC Filings
GMAB's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
In the Idea Lab
GMAB — frequently asked questions
Is GMAB a good stock to buy?
We don't give buy or sell advice. Our model rates Genmab A/S Favorable (62/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is GMAB's rating on The Stocks School?
Genmab A/S currently scores 62/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does GMAB's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Genmab A/S's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for GMAB calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this GMAB analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell GMAB. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.